| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Altimmune, Inc. (ALT) has 16 insiders with recent SEC Form 4 filings, including 26 buys and 0 sells. ALT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 420.3K | $1.13M | - | |
| Other | 150.0K | $405.0K | - | |
| Other | 100.1K | $270.4K | - | |
| Other | 96.0K | $259.2K | - | |
| Dir | 48.8K | $131.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 27, 2017 | Schaffer Derace L | Director | Buy | 147,130 | $1.76 | $259,356.40 | +9.3% | |
| Dec 7, 2017 | Schaffer Derace L | Director | Buy | 23,745 | $1.78 | $42,303.53 | +3.6% | |
| Dec 5, 2017 | Schaffer Derace L | Director | Buy | 26,010 | $1.79 | $46,587.57 | +2.9% | |
| Nov 30, 2017 | Schaffer Derace L | Director | Buy | 33,315 | $1.91 | $63,638.65 | +4.1% | |
| Nov 27, 2017 | Schaffer Derace L | Director | Buy | 21,808 | $2.03 | $44,282.19 | +3.0% | |
| Nov 21, 2017 | Schaffer Derace L | Director | Buy | 18,331 | $2.08 | $38,214.73 | +2.7% | |
| Aug 25, 2017 | Schaffer Derace L | Director | Buy | 67,326 | $2.25 | $151,281.67 | +20.6% | |
| Aug 23, 2017 | Drutz David65 | Director | Buy | 10,000 | $2.21 | $22,097.00 | +21.5% | |
| Aug 23, 2017 | Schaffer Derace L | Director | Buy | 50,000 | $2.21 | $110,263.47 | +15.6% | |
| Jun 6, 2017 | Roberts M Scot67 | Chief Scientific Officer | Buy | 449 | $4.42 | $1,984.58 | New |